Towards integration of 64Cu-DOTA-trastuzumab PET-CT and MRI with mathematical modeling to predict response to neoadjuvant therapy in HER2 + breast cancer
Abstract While targeted therapies exist for human epidermal growth factor receptor 2 positive (HER2 +) breast cancer, HER2 + patients do not always respond to therapy. We present the results of utilizing a biophysical mathematical model to predict tumor response for two HER2 + breast cancer patients...
Main Authors: | Angela M. Jarrett, David A. Hormuth, Vikram Adhikarla, Prativa Sahoo, Daniel Abler, Lusine Tumyan, Daniel Schmolze, Joanne Mortimer, Russell C. Rockne, Thomas E. Yankeelov |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2020-11-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-020-77397-0 |
Similar Items
-
Synthesis and stability test of radioimmunoconjugate 177Lu-DOTA-F(ab′)2-trastuzumab for theranostic agent of HER2 positive breast cancer
by: Sandra Hermanto, et al.
Published: (2016-10-01) -
Neoadjuvant Trastuzumab Concurrent with Nonanthracycline-based Regimens for HER2-positive Locally Advanced Breast Cancer
by: Wei-Hsin Liu, et al.
Published: (2014-09-01) -
Fractionated therapy of HER2-expressing breast and ovarian cancer xenografts in mice with targeted alpha emitting 227Th-DOTA-p-benzyl-trastuzumab.
by: Helen Heyerdahl, et al.
Published: (2012-01-01) -
NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer
by: Samuel A. Jacobs, et al.
Published: (2019-12-01) -
Nab-paclitaxel and trastuzumab combination: a promising approach for neoadjuvant treatment in HER2-positive breast cancer
by: Ricciardi GR, et al.
Published: (2016-07-01)